Mesoblast Rheumatoid Arthritis Trial Results Presented at EULAR Annual European Congress of Rheumatology
June 22 2017 - 6:00AM
Mesoblast Limited (Nasdaq:MESO) (ASX:MSB) announced that
results from the randomized, placebo-controlled 48-patient
Phase 2 trial of its proprietary allogeneic Mesenchymal Precursor
Cells (MPCs) in patients with biologic refractory rheumatoid
arthritis (RA) were presented at the European League Against
Rheumatism (EULAR) Annual European Congress of Rheumatology held in
Madrid June 14-17. The abstract was selected by peer review and
presented by the trial’s independent investigators.
The EULAR Congress is the key European
platform for showcasing innovation in rheumatology
and highlighting the latest advances in the field. The 2017
Congress was attended by approximately 14,000 delegates from more
than 120 countries.
Trial investigator, Dr Suzanne Kafaja, Assistant
Clinical Professor in the Division of Rheumatology, Department
of Medicine, at the University of California at Los Angeles
(UCLA), presented both safety and efficacy outcomes of the trial
using pre-specified analyses over the 12-week primary evaluation
period, as well as follow-up results over 39 weeks.
Dr Kafaja said the trial had met its primary endpoints and the
data indicated an early trend to improvements in patient-related
outcome measures. “Taken together, these results show promise and
support further development of Mesoblast's mesenchymal precursor
cells for biologic-refractory rheumatoid arthritis patients, a
population with substantial remaining medical need," she said.
Major advances in the treatment of RA using biologic agents have
resulted in a $19 billion global market in 2016, the majority of
which is due to use of anti-TNF agents. The RA population resistant
to anti-TNF agents, which constitutes about one-third of patients
treated with anti-TNF agents, is the fastest growing branded market
segment within the global RA biologics market, and is set to grow
further as multiple anti-TNF biosimilars become available. There
are approximately 6 million prevalent cases in the United States,
Japan, and EU5, with 2.9 million in the United States alone in
20161,2
1. GlobalData©: Rheumatoid Arthritis Global Forecast 2015-2025
0- January 20172. Decision Resources Rheumatoid Arthritis Dec
2015
About MesoblastMesoblast Limited (Nasdaq:MESO)
(ASX:MSB) is a global leader in developing innovative cell-based
medicines. The Company has leveraged its proprietary technology
platform, which is based on specialized cells known as mesenchymal
lineage adult stem cells, to establish a broad portfolio of
late-stage product candidates. Mesoblast’s allogeneic,
‘off-the-shelf’ cell product candidates target advanced stages of
diseases with high, unmet medical needs including cardiovascular
conditions, orthopedic disorders, immunologic and inflammatory
disorders and oncologic/hematologic conditions.
Forward-Looking StatementsThis press release
includes forward-looking statements that relate to future events or
our future financial performance and involve known and unknown
risks, uncertainties and other factors that may cause our actual
results, levels of activity, performance or achievements to differ
materially from any future results, levels of activity, performance
or achievements expressed or implied by these forward-looking
statements. We make such forward-looking statements pursuant to the
safe harbor provisions of the Private Securities Litigation Reform
Act of 1995 and other federal securities laws.
Forward-looking statements should not be read as a guarantee of
future performance or results, and actual results may differ from
the results anticipated in these forward-looking statements, and
the differences may be material and adverse. You should read this
press release together with our risk factors, in our most recently
filed reports with the SEC or on our website. Uncertainties and
risks that may cause Mesoblast's actual results, performance or
achievements to be materially different from those which may be
expressed or implied by such statements, and accordingly, you
should not place undue reliance on these forward-looking
statements. We do not undertake any obligations to publicly update
or revise any forward-looking statements, whether as a result of
new information, future developments or otherwise.
For further information, please contact:
Julie Meldrum
Corporate Communications
T: +61 3 9639 6036
E: julie.meldrum@mesoblast.com
Schond Greenway
Investor Relations
T: +1 212 880 2060
E: schond.greenway@mesoblast.com
Mesoblast (NASDAQ:MESO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Mesoblast (NASDAQ:MESO)
Historical Stock Chart
From Apr 2023 to Apr 2024